- Home
- RXO vs DNTH Comparison
RXO vs DNTH Comparison
Compare RXO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXO | DNTH |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.5B |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RXO | DNTH |
|---|---|---|
| Price | $25.29 | $82.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $16.33 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 2.1M | 926.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000,000.00 | $2,036,000.00 |
| Revenue This Year | $0.49 | N/A |
| Revenue Next Year | $6.90 | $29.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $10.43 | $18.08 |
| 52 Week High | $29.86 | $96.50 |
Technical Indicators
Market Signals| Indicator | RXO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 48.32 |
| Support Level | $16.80 | $79.27 |
| Resistance Level | $29.86 | $92.41 |
| Average True Range (ATR) | 1.54 | 5.51 |
| MACD | -0.52 | -0.15 |
| Stochastic Oscillator | 13.71 | 57.80 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.